company logo

Associate Director, Compliance & Audit at AstraZeneca in Wilmington, DE

Save

compensation:

$80K — $100K *

specialty:

Auditing & Compliance

experience:

5 - 7 years

Job Description

See More

Valid through: 3/8/2021

About AstraZeneca

MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA. It produced Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune acquired FluMist when it purchased Aviron in 2002 for US$ 1.5 billion. FluMist sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006. FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market—young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store. MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was approved by the U.S. Food and Drug Administration in 2007, and is now the form offered on the market.
stats icon
Total Jobs:
123
stats icon
Total Experts:
42
stats icon
Average Pay:
$123,904
stats icon
Total value of jobs:
$39,030,000
stats icon
% Masters:
35%
Learn More About AstraZeneca view all icon
* Ladders Estimates